NCT04332653 - NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

215

Participants

Timeline

Start Date

June 10, 2020

Primary Completion Date

November 22, 2024

Study Completion Date

January 13, 2025

Conditions

Any Advanced Solid TumorsTriple Negative Breast CancerNon Small Cell Lung CancerSmall Cell Lung CancerMicrosatellite Stable Colorectal CancerPancreatic CancerOvarian Cancer

Interventions

DRUG

NT-I7

Administered by intramuscular (IM) injection

DRUG

pembrolizumab (KEYTRUDA®)

Administered by intravenous (IV) injection

Trial Locations (8)

19111

Fox Chase Cancer Center, Philadelphia

27710

Duke University Medical Center, Durham

33612

Moffit Cancer Center, Tampa

37211

Sarah Cannon Research Institute, Nashville

48201

Barbara Ann Karmanos Cancer Institute, Detroit

63110

Washington University School of Medicine in St. Louis, St Louis

75230

Mary Crowley Cancer Research, Dallas

77030

MD Anderson Cancer Center, Houston